Date: 2016-04-21
Type of information: Interim results
phase: 2-3
Announcement: interim results
Company: Novartis (Switzerland)
Product: bimagrumab (BYM338)
Action
mechanism: monoclonal antibody. Bimagrumab (BYM338) is a fully human monoclonal antibody developed to treat pathological muscle loss and weakness. Bimagrumab was developed by the Novartis Institutes for Biomedical Research (NIBR), in collaboration with MorphoSys, whose HuCAL library was used to identify the antibody. Bimagrumab binds with high affinity to type II activin receptors, preventing natural ligands from binding, including myostatin and activin. Bimagrumab stimulates muscle growth by blocking signaling from these inhibitory molecules.
Disease: sporadic inclusion body myositis (sIBM)
Therapeutic area: Inflammatory diseases - Rare diseases
Country:
Trial details:
Latest
news: * On April 21, 2016, MorphoSys announced that Novartis has confirmed that a phase 2b/3 study examining bimagrumab (BYM338) in sporadic Inclusion Body Myositis (sIBM) did not meet its primary endpoint. Data are currently being reviewed and will inform decisions on the bimagrumab development program. Ongoing clinical trials are not being discontinued at this time.
* On Octobre 3, 2013, MorphoSys has announced that Novartis has initiated a phase 2/3 clinical trial in sporadic inclusion body myositis (sIBM) patients with the HuCAL-derived antibody bimagrumab (BYM338). The event triggered a clinical milestone payment to MorphoSys. Further financial details were not disclosed.
